Business
HEALTH CANADA GRANTS VIVIMIND¿ A NATURAL HEALTH PRODUCT NUMBER
HEALTH CANADA GRANTS VIVIMIND¿ A NATURAL HEALTH PRODUCT NUMBER
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n Sep. 30, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\n VIVIMIND™, a natural health product for the brain, is formally\n authorized for sale in Canada\n \n\n LAVAL,QC, Sept. 30 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS\n Health" or the "Company") announced today that a Natural Health Product\n Number ("NPN") has been issued by Health Canada for VIVIMIND™, a\n patented natural health product commercialized by OVOS Natural Health,\n the Company's wholly owned subsidiary. The NPN grants VIVIMIND™ formal\n authorization for sale in Canada.\n \n\n VIVIMIND™ is scientifically proven to help support the specific area of\n the brain known as the hippocampus, a region responsible for memory and\n learning. The active ingredient behind VIVIMIND™, homotaurine, is a\n naturally occurring amino acid with unique properties found in certain\n seaweed. VIVIMIND™ is intended to be used in normal aging adults.\n \n\n VIVIMIND™ was subject to over 15 years of significant scientific\n research, including clinical testing in over 2,000 individuals in\n European, American and Canadian medical centers. In a large controlled\n clinical study, VIVIMIND™ was shown to reduce by 68% the hippocampus\n volume loss in Alzheimer's disease patients over 18 months.1\n Regulatory approvals for the commercial sale of VIVIMIND™ were obtained\n in Italy and in Spain in 2009.\n \n\n "We are v...